Furthermore, the frequency of MDM2 polymorphism in the UCB patients, did not differ from that noted in our reference population, and it was in Hardy-Weinberg equilibrium, which suggests that such polymorphism is stable during tumor development, and consequently there is no difference between benign and malignant cells. This evidence concerns the gene MDM2 and neoplasm.